Gilead Sciences (GILD) PT Raised at Cowen as HCV Sales Drive Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy
October 28, 2015 1:47 PM EDTMaxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00), following the company's 3Q earnings results. Gilead delivered a very strong quarter well ahead of street estimates. Gilead raised guidance for full year... More
Gilead Sciences (GILD) Bullish Stance Reiterated at Oppenheimer Amid 'Beat and Raise' Qtr
October 28, 2015 6:25 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and $124 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q3.
Lam commented, "GILD reported a healthy 3Q15 beat, with revenue and non-GAAP EPS of $8.30B and $3.22 topping Street consensus estimates of $7.81B and $2.87; GILD... More
Gilead (GILD) Slips Despite Strong Q3 Results
October 27, 2015 4:13 PM EDTGilead (NASDAQ: GILD) reported third quarter financial results today after the market close and the stock is trading down by 1.8% in the aftermarket. Revenue of $8.7 billion beat expectations of $7.8 billion. EPS of $3.22 beat consensus of $2.83.
Breaking down the numbers by therapy, HCV... More
Gilead Sciences (GILD) Tops Q3 EPS by 33c, Updates FY15 Guidance
October 27, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $8.3 billion versus the consensus estimate of $7.82 billion.
Product Sales
Total product sales for the third quarter of 2015 were $8.2 billion compared to $6.0... More
